Business Context and Reporting Period
This summary covers the Form 10-Q for Galecto, Inc. (Note: The request metadata listed "Damora Therapeutics," but the filing text identifies the registrant as Galecto, Inc., trading under symbol GLTO). The report covers the quarterly period ended June 30, 2025. Galecto is a clinical-stage biotechnology company that recently realigned its strategy to focus exclusively on two product candidates: GB3226 (a dual ENL-YEATS and FLT3 inhibitor for acute myeloid leukemia) and GB1211 (a galectin-3 inhibitor for oncology and liver disease). The company discontinued its previous candidate, GB2064, as part of a strategic restructuring.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(3.4) million | $(6.0) million | $(10.8) million |
| Operating Expenses | $(3.4) million | $(6.0) million | $(11.3) million |
| Cash and Cash Equivalents | $10.2 million (as of June 30, 2025) | $10.2 million | $22.9 million (as of June 30, 2024) |
| Net Cash Used in Operating Activities | N/A | $(4.7) million | $(10.0) million |
| Accumulated Deficit | $(283.5) million | $(283.5) million | $(266.9) million |
Liquidity: As of June 30, 2025, the company held $10.2 million in cash and cash equivalents. Current assets totaled $13.0 million against current liabilities of $2.6 million.
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased by 38.7% in Q2 2025 compared to Q2 2024 ($3.4M vs. $5.6M) and by 46.8% on a year-to-date basis ($6.0M vs. $11.3M). This reduction is primarily due to the elimination of restructuring costs ($0.97M in Q2 2024) and significant decreases in personnel and consulting costs following the strategic restructuring.
- Research & Development (R&D): R&D expenses decreased 20.1% in Q2 2025. While personnel and clinical trial costs dropped significantly, chemistry, manufacturing, and control (CMC) costs increased by 678% in Q2 2025 due to the acquisition and advancement of the GB3226 program.
- Other Income: Other income, net, turned negative in Q2 2025 ($(0.012)M) compared to positive income in Q2 2024 ($0.281M), driven by lower interest income from reduced cash balances and foreign exchange losses.
- Stock-Based Compensation: Stock-based compensation expense dropped significantly to $0.35 million for the six months ended June 30, 2025, compared to $2.25 million in the same period in 2024.
Guidance, Outlook, and Risks
- Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern for at least one year from the issuance date. The company estimates its current cash of $10.2 million will be sufficient to fund preclinical development of GB3226 into 2026 (including an IND submission) but is insufficient for clinical development or long-term operations without additional funding.
- Funding Needs: The company plans to raise additional capital through equity or convertible debt financings and/or collaborations. There is no assurance that such funding will be available on acceptable terms.
- Strategic Milestones:
- GB3226: Plans to submit an Investigational New Drug (IND) application to the FDA in Q1 2026. Initial clinical data is expected in 2027.
- GB1211: Continuing an investigator-initiated Phase 2 trial in combination with pembrolizumab for melanoma and HNSCC. The company does not intend to initiate Part B of the GALLANT-1 trial.
- Risks: Key risks include the failure to secure additional financing, potential delisting from Nasdaq, reliance on the success of two product candidates, and the inherent uncertainties of clinical development and regulatory approval.
Investor Verification Checklist
- Cash Runway: Verify the specific timeline for cash exhaustion and the status of any ongoing fundraising efforts or bridge financing.
- GB3226 Acquisition: Review the terms of the Asset Purchase Agreement with Bridge Medicines and the specific liabilities assumed.
- Preferred Stock Conversion: Note the conversion of Series A Preferred Stock into common stock in June 2025 and its impact on share count and dilution.
- Going Concern Disclosure: Assess the severity of the "substantial doubt" disclosure and the specific contingency plans outlined by management.
- CMC Cost Spike: Investigate the 678% increase in chemistry, manufacturing, and control costs in Q2 2025 to understand the capital intensity of the new GB3226 program.